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Background: Early treatment response markers, for example, improvement in forced expiratory 
volume in 1 second (FEV
1
) and St George’s Respiratory Questionnaire (SGRQ) total score, may 
help clinicians to better manage patients with chronic obstructive pulmonary disease (COPD). 
We investigated the prevalence of clinically important improvements in FEV
1
 and SGRQ scores 
after 2-month budesonide/formoterol or formoterol treatment and whether such improvements 
predict subsequent improvements and exacerbation rates.
Methods: This post hoc analysis is based on data from three double-blind, randomized studies 
in patients with moderate-to-very-severe COPD receiving twice-daily budesonide/formoterol 
or formoterol alone for 6 or 12 months. Prebronchodilator FEV
1
 and SGRQ total score were 
measured before treatment and at 2 and 12 months; COPD exacerbation rates were measured 
during months 2–12. Responders were defined by $100 mL improvement in prebronchodilator 
FEV
1
 and $4-point decrease in SGRQ total score.
Results: Overall, 2,331 and 1,799 patients were included in the 0–2- and 0–12-month responder 
analyses, respectively, and 2,360 patients in the 2–12-month exacerbation rate analysis. 
At 2 months, 35.1% of patients were FEV
1
 responders and 44.3% were SGRQ responders. 
The probability of response was significantly greater with budesonide/formoterol than with 
formoterol or placebo for both parameters. Two-month responders had a greater chance of 
12-month response than 2-month nonresponders for both FEV
1
 (odds ratio, 5.57; 95% confi-
dence interval, 4.14–7.50) and SGRQ (odds ratio, 3.87; 95% confidence interval, 2.83–5.31). 
Two-month response in FEV
1
 (P,0.001), but not SGRQ (P=0.11), was associated with greater 
reductions in exacerbation risk.
Conclusion: Early FEV
1
 and SGRQ treatment responses relate to their changes at 12 months. 
FEV
1
 response, but not SGRQ response, at 2 months predicts the risk of a future COPD exac-
erbation in some, but not all patients. This is potentially useful in clinical practice, although 
more sensitive and specific markers of favorable treatment response are required.
Keywords: anti-inflammatories, bronchodilator effect, chronic obstructive pulmonary disease, 




-agonists (LABAs), alone or in combination with inhaled 
corticosteroids (ICS), improve lung function and clinical outcomes in patients 
with chronic obstructive pulmonary disease (COPD).1–3 Some outcomes, such as 
improvements in exercise capacity and breathlessness, occur after a single dose of 
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a bronchodilator.4,5 However, for other important events, 
such as exacerbations, time must elapse before the effect of 
treatment is clear. The current recommendations for treat-
ments that prevent exacerbations, an important future risk 
for patients with COPD,6 are based on the average benefit of 
therapy seen in large patient populations, normally in trials of 
12 months’ duration. Identification of an easily measurable 
disease marker that identifies individuals likely to benefit 
from continued treatment would aid clinical decision making 
and prognostication.
Two potential markers of early treatment effect are the 
change in lung function and in health status during treatment, 
evaluated by change in forced expiratory volume in 1 second 
(FEV
1
) and St George’s Respiratory Questionnaire (SGRQ) 
total score, respectively. Both markers improve within days or 
weeks of bronchodilator treatment,7–9 and each has a defined 
clinically important difference (CID) that could serve as a 
threshold to identify change. A 100 mL increase in FEV
1
 dur-
ing the recovery period from an exacerbation identified patients 
less likely to have a subsequent relapse, lending support to the 
utility of this threshold for CID.10 However, before accepting 
these variables as being useful, it is crucial to determine: 1) the 
prevalence of early CID in these outcomes related to treatment; 
2) the consistency of early responses over time; and 3) the 
impact of early response on future exacerbation risk.
To address these questions, we performed a post hoc 
analysis of data from published trials in which the LABA for-
moterol, given alone via a dry powder inhaler, was compared 
with a fixed-dose combination of formoterol and the ICS 
budesonide, given via a pressurized metered-dose inhaler, 
over 6–12 months in patients with moderate-to-very-severe 
COPD at risk of exacerbations.3,11,12
Methods
study design and patient population
This post hoc analysis is based on data from three multicenter, 
randomized, double-blind, double-dummy, parallel-group clin-
ical trials of 6 (ClinicalTrials.gov identifier: NCT002061543) 
and 12 (NCT0020616711 and NCT0041974412) months’ dura-
tion in patients with moderate-to-very-severe COPD.
The studies recruited patients $40 years of age with 
COPD and symptoms for .2 years, a smoking history of $10 
pack-years, prebronchodilator FEV
1
 #50% predicted, FEV
1
/
forced vital capacity ratio of ,0.7, modified Medical Research 
Council dyspnea score $2, and a history of $1 COPD exac-
erbation requiring systemic corticosteroids and/or antibiotics 
within 1–12 months of inclusion. Patients were randomized 
to receive two inhalations twice daily of budesonide/formot-
erol 160/4.5 µg (via pressurized metered-dose inhaler) or 
formoterol 4.5 µg (via dry powder inhaler) for 63 or 1211,12 
months. Two studies3,11 included a placebo control group. 
All participants provided written informed consent and the 
studies received appropriate ethical approval.
study assessments
All studies assessed prebronchodilator FEV
1
 and SGRQ 
total score at baseline and 2 months postrandomization and, 
in two of the studies,11,12 also at 12 months. Spirometry was 
performed according to the American Thoracic Society 
guidelines.13 COPD exacerbations, defined as worsening 
symptoms requiring oral corticosteroids and/or hospitaliza-
tion, were recorded throughout the study periods.
In the present analysis, changes in FEV
1
 ($100 mL 
improvement in prebronchodilator FEV
1
8,14,15) and SGRQ 
total score ($4-point decrease [ie, an improvement]16) 
from 0 to 2 months were used as thresholds to investigate 
the frequency of response over 0–2 months of treatment 
(a commonly used clinical follow-up interval). From these 
2-month responses, we investigated: 1) the stability of early 
2-month FEV
1
 and SGRQ responses in the two 12-month 
studies11,12 and 2) the rate of exacerbations during months 
2–12 in the responder subgroups of all three studies.3,11,12 
Data from the placebo-controlled studies3,11 were analyzed 
to provide information about spontaneous improvement in 
the early response measurement. The 6-month study was 
included in order to evaluate short-term response, including 
placebo as a control; this approach was necessary in order 
to achieve the optimum number of patients.
Data analyses and statistical methods
Both FEV
1
 and SGRQ data were described as continuous 




 and SGRQ total score from 0 to 
2 months were compared between treatments using analysis 
of variance, with treatment and study as factors and the base-
line value as a covariate. The proportion of patients achieving 
an FEV
1
 or SGRQ response during 0–2 months was compared 
between all treatments using logistic-regression analysis, 
with treatment and study as factors. The responder analysis 
from 0 to 2 months postrandomization excluded patients with 
missing baseline FEV
1
 or SGRQ total score data.
The 0–12-month analysis was restricted to the formot-
erol and budesonide/formoterol groups because of high 
dropout rates in the placebo groups during the follow-up 
period of the studies, a finding noted previously.17 Changes 
in FEV
1
 and SGRQ total score from 0 to 12 months were 
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early treatment responses as predictors in COPD
factors and baseline values and change from 0 to 2 months 
as covariates. The odds ratio (OR), with 95% confidence 
intervals (CIs), of being a 12-month responder was analyzed 
using logistic-regression analysis with study, treatment, and 
2-month response as factors. The interaction between treat-
ment allocation and 2-month FEV
1
 and SGRQ response rates 
was also investigated.
In subjects achieving thresholds of $100 mL improve-
ment in FEV
1
 and a decrease of $4 points in SGRQ total 
score at 2 months, exacerbation rates (events per patient 
per year) by response and treatment were estimated using a 
Poisson model, with treatment, study, response, and treatment 
response interaction as factors. Rate ratios between treat-
ments and response groups, with 95% CIs and P-values, were 
calculated. In addition, exacerbation rates after the 2-month 
visit were analyzed using a Poisson model with treatment and 
study as factors; covariates were baseline values and change 
in FEV
1
 and SGRQ total scores over 0–2 months, adjusted 
for the remaining observation time and over-dispersion.
Results
Patient demographics and clinical 
characteristics
A total of 2,331 and 1,799 patients were included in the 
0–23,11 and 0–12-month11,12 responder analyses, respec-
tively, and 2,360 patients were included in the 2–12-month 
exacerbation rate analysis.3,11,12 Missing data are described 
in the supplementary materials. There were no significant 
differences in baseline clinical or demographic character-
istics among the three analyses (Table 1) and between the 
three different treatment groups included in the 0–2-month 
responder analysis (Table 2).
Table 1 Demographic and clinical characteristics of patients who received budesonide/formoterol, formoterol alone, or placebo 
in the 0–2-month responder analysis, and budesonide/formoterol or formoterol alone in the 12-month response and 2–12-month 
exacerbation rate analysesa
Characteristics 0–2-month response analysis 
(n=2,331)
12-month response analysis 
(n=1,799)
Exacerbation rate analysis 
(n=2,360)
age, years 63.1 (9.2) 63.1 (9.2) 63.1 (9.2)
Male, n (%) 1,526 (65.5) 1,122 (62.4) 1,496 (63.4)
BMI, kg/m2 26.8 (5.7) 26.7 (5.9) 26.6 (5.8)
Time since first symptoms, months 127.2 (84.8) 126.5 (85.3) 125.6 (85.2)
FeV1 parameters
Prebronchodilator, % predicted 34.2 (9.7) 34.7 (10.4) 34.4 (10.3)
Prebronchodilator,b l 1.0 (0.4) 1.0 (0.4) 1.0 (0.4)
reversibility, % predicted 5.5 (5.9) 5.4 (5.6) 5.4 (5.6)
Postbronchodilator, % predicted 39.7 (11.9) 40.0 (12.4) 39.9 (12.4)
Prebronchodilator FeV1/FVC, % 47.6 (10.4) 47.0 (10.8) 46.8 (10.7)
smoking history
Median, pack-years 40.0 43.0 42.0
Former smokers, n (%) 1,343 (57.6) 1,091 (60.6) 1,410 (59.8)
Current smokers, n (%) 988 (42.4) 708 (39.4) 950 (40.3)
sgrQ total score,b points (range) 54.9 (6.7–100.0) 56.1 (6.2–100.0) 55.8 (6.2–100.0)
reliever use, no of inhalations (range) 3.7 (0.0–32.5) 4.8 (0.0–33.8) 4.5 (0.0–33.8)
COPD severity (gOlD grades),c n (%)
II (moderate) 436 (18.7) 386 (21.6) 497 (21.2)
III (severe) 1,364 (58.5) 981 (55.0) 1,288 (54.9)
IV (very severe) 522 (22.4) 414 (23.2) 555 (23.7)
number of COPD maintenance  
medications,d n (%) 
0 587 (25.2) 475 (26.5) 597 (25.4)
1 537 (23.0) 440 (24.6) 548 (23.3)
2 695 (29.8) 569 (31.8) 760 (32.3)
3 512 (22.0) 307 (17.1) 447 (19.0)
Notes: Data are given as mean (sD), unless otherwise stated. aassessments of FeV1 and sgrQ were completed at baseline and month 2 (0–2-month responder analysis), and 
at baseline and months 2 and 12 (12-month responder and exacerbation rate analyses). bMeasured at randomization. cGOLD COPD grades are defined as follows: grade II, 
postbronchodilator FeV1 50%–80% of predicted; grade III, postbronchodilator FeV1 30%–50% of predicted; and grade IV, postbronchodilator FeV1 ,30% of predicted. 
dThe 
number of COPD maintenance medications is defined as follows: 0, no maintenance treatment with LA or ICS (short-acting bronchodilators only); 1, one LA or ICS; 2, two 
la or ICs; 3, three la or ICs. all patients received short-acting β2-agonists at inclusion so that a reversibility test could be conducted (GOLD classification based upon 
postbronchodilator FeV1). The majority of patients with a prebronchodilator FeV1 of 40%–50% had a postbronchodilator FeV1 of $50%, thus classifying them as having 
moderate COPD. Patients were recruited if they displayed a prebronchodilator FeV1 of #50%, but only postbronchodilator FeV1 values are presented here.
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; gOlD, 
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Two-month response in FeV1 and sgrQ 
as a predictor of longer-term response 
to ICs/laBa or laBa
At 2 months, an FEV
1
 response ($100 mL improvement) 
was seen in 35.1% of patients (Figure S1A) and an SGRQ 
response ($4-point improvement in total score) was seen in 
44.3% of patients (Figure S2A). FEV
1
 responders had bet-
ter baseline lung function and SGRQ responders had higher 
initial SGRQ total scores than the respective nonresponders 
(Tables S1 and S2). Responders took fewer maintenance 
medications (long-acting bronchodilators or ICS) at study 
entry than nonresponders (Tables S1 and S2).
The odds of being an FEV
1
 and SGRQ responder were 
significantly greater with budesonide/formoterol versus 
formoterol alone (OR, 1.56 [P,0.001] and OR, 1.36 
[P,0.006], respectively) and for budesonide/formoterol 
versus placebo (OR, 2.21 [P,0.001] and OR, 1.42 [P=0.002], 
respectively) (Table 3). The budesonide/formoterol group 
had higher response rates than either formoterol- or 
placebo-treated patients over a range of cut-points for FEV
1
 
and SGRQ score (Figure 1A and B, respectively).
At 12 months, the prespecified FEV
1
 and SGRQ 
responses were seen in 36.0% (Figure S1B) and 49.0% 
(Figure S2B) of patients, respectively. Responses at 2 months 
were highly predictive of 12-month response: an FEV
1
 
response at 12 months was 5.6 times more likely among 
2-month responders than nonresponders (OR, 5.57; 95% CI, 
4.14–7.50; P,0.001) and a 12-month SGRQ response was 
3.9 times more likely if the patient responded at 2 months 
(OR, 3.87; 95% CI, 2.83–5.31; P,0.001).
Two-month response in FeV1 and sgrQ 
as a predictor of exacerbations
Exacerbations during months 2–12 were significantly less 
frequent in FEV
1
 2-month responders than in nonresponders 
(P,0.001; Table 4). This effect was observed in both 
Table 2 Demographic and clinical characteristics for all patients who received budesonide/formoterol, formoterol, or placebo, and by 









age, years 63.1 (9.2) 63.2 (9.0) 63.1 (9.3) 63.0 (9.3)
Male, n (%) 1,526 (65.5) 496 (64.3) 509 (65.3) 521 (66.7)
BMI, kg/m2 26.8 (5.7) 26.6 (5.6) 26.8 (5.6) 27.0 (5.9)
Time since first symptoms, months 127.2 (84.8) 126.0 (84.0) 128.4 (85.1) 127.1 (85.3)
FeV1
Prebronchodilator, % predicted 34.2 (9.7) 33.3 (9.6) 34.1 (9.9) 35.1 (9.4)
Prebronchodilator, la 1.0 (0.4) 1.0 (0.4) 1.0 (0.4) 1.1 (0.4)
reversibility, % predicted 5.5 (5.9) 5.4 (5.3) 5.3 (5.8) 5.8 (6.5)
Postbronchodilator, % predicted 39.7 (11.9) 38.8 (11.5) 39.4 (12.2) 41.0 (11.8)
Prebronchodilator FeV1/FVC, % 47.6 (10.4) 47.1 (10.4) 47.5 (10.5) 48.3 (10.3)
smoking history
Median, pack-years 40.0 40.0 40.0 40.0
Former smokers, n (%) 1,343 (57.6) 455 (59.0) 437 (56.1) 451 (57.7)
Current smokers, n (%) 988 (42.4) 316 (41.0) 342 (43.9) 330 (42.3)
sgrQ total score,a points (range) 54.9 (6.7–100.0) 55.2 (6.7–100.0) 54.7 (16.4–97.4) 54.7 (8.8–96.9)
reliever use, no of inhalations (range) 3.7 (0.0–32.5) 3.7 (0.0–21.6) 3.9 (0.0–32.5) 3.5 (0.0–28.0)
COPD severity (gOlD grades),b n (%)
II (moderate) 436 (18.7) 136 (17.6) 148 (19.0) 152 (19.5)
III (severe) 1,364 (58.9) 443 (57.5) 439 (56.4) 482 (61.7)
IV (very severe) 522 (22.4) 191 (24.8) 189 (24.3) 142 (18.2)
no of COPD maintenance medications,c n (%)
0 587 (25.2) 186 (24.1) 195 (25.0) 206 (26.4)
1 537 (23.0) 176 (22.8) 187 (24.0) 174 (22.3)
2 695 (29.8) 246 (31.9) 222 (28.5) 227 (29.1)
3 512 (22.0) 163 (21.1) 175 (22.5) 174 (22.3)
Notes: Data are given as mean (sD), unless otherwise stated. aMeasured at randomization. bGOLD COPD grades are defined as follows: grade II, postbronchodilator 
FeV1 50%–80% of predicted; grade III, postbronchodilator FeV1 30%–50% of predicted; and grade IV, postbronchodilator FeV1 ,30% of predicted. 
cThe number of COPD 
maintenance medications is defined as follows: 0, no maintenance treatment with LA or ICS (short-acting bronchodilators only); 1, one LA or ICS; 2, two LA or ICS; and 
3, three la or ICs.
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; gOlD, 
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early treatment responses as predictors in COPD
treatment groups. In 2-month FEV
1
 responders, reductions 
in 12-month exacerbation rates were similar for budesonide/
formoterol and formoterol alone (Table 4). In 2-month 
FEV
1
 nonresponders, the 12-month exacerbation rate was 
significantly lower for budesonide/formoterol-treated 
patients compared with formoterol alone (P=0.015; Table 4; 
Figure 2A). Exacerbation frequency during months 2–12 
was unrelated to SGRQ response at 2 months (32.2% vs 
34.2%; Table 4; Figure 2B). However, exacerbations were 
less frequent with the budesonide/formoterol combina-
tion, irrespective of 2-month SGRQ response (Table 4; 
Figure 2B).
A Poisson analysis with treatment, baseline, and 2-month 
response as factors showed that improvements in 2-month 
FEV
1
 of $100 mL and SGRQ total score of $4 points 
were associated with an 8% and 5% decrease, respectively, 
in exacerbation frequency during months 2–12 (Table 5). 
Greater FEV
1
 (100 mL) and lower SGRQ score (-4 points) 
at baseline were also predictive of a decrease in exacerbation 
frequency (Table 5).
Discussion
In this post hoc analysis of data from published trials, we have 
shown that: 1) improvements in FEV
1
 and SGRQ total score 
after 12 months are more likely to be observed in patients 
showing an early 2-month treatment response compared with 
2-month nonresponders; 2) a 2-month treatment response in 
FEV
1
, but not SGRQ, was associated with greater reductions 
Table 3 analysis of 2-month response rates in FeV1 and sgrQ total score in patients who received budesonide/formoterol, formoterol 
alone, or placebo in the two placebo-controlled trials
FEV1 response
a SGRQ responseb
OR (95% CI) P-value OR (95% CI) P-value
Odds of achieving response vs nonresponse
Budesonide/formoterol 0.79 (0.68–0.92) 0.98 (0.84–1.15)
Formoterol 0.51 (0.43–0.60) 0.72 (0.62–0.85)
Placebo 0.36 (0.30–0.43) 0.69 (0.59–0.82)
Odds of achieving response with one treatment vs another
Budesonide/formoterol vs formoterol 1.56 (1.25–1.95) ,0.001 1.36 (1.09–1.70) 0.006
Budesonide/formoterol vs placebo 2.21 (1.75–2.79) ,0.001 1.42 (1.13–1.78) 0.002
Formoterol vs placebo 1.42 (1.12–1.81) 0.004 1.04 (0.83–1.31) 0.72
Notes: aFeV1 response was defined as an improvement in the FEV1 of $100 ml. 
bSGRQ response was defined as an improvement (ie, reduction) in SGRQ total score 
of $4 points.


















































Figure 1 Cumulative distribution of (A) FeV1 response and (B) sgrQ response at 2 months in patients who received budesonide/formoterol, formoterol alone, or placebo, 
by treatment, according to multiple cut-points. 
Note: Vertical lines represent the predefined response cut-offs (+100 ml for FeV1 and -4 points for sgrQ total score).
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in exacerbation risk; and 3) 2-month FEV
1
 and SGRQ non-
responders had fewer exacerbations if they received an ICS/
LABA rather than a LABA alone. These data help set the 
“early response” to treatment in a wider context.
Our analysis sought to establish whether early responses 
to treatment have predictive ability by measuring changes 
in FEV
1
 and SGRQ total score after 2 months of treatment. 
It was expected that changes in these variables would be 
clinically noticeable after 2 months, a follow-up interval 
commonly used in clinical practice when assessing the 
impact of treatment in patients with COPD. Although some-
what arbitrary, an improvement of 100 mL in FEV
1
 appears 
to be a reasonable threshold as it exceeds the day-to-day 
reproducibility of this measurement in patients with COPD,18 
identifies patients with a lower risk of relapse during recov-
ery from an acute event,8 and has previously been proposed 
Table 4 Poisson regression analysis of exacerbation rates, by treatment, during months 2–12 in patients who received budesonide/









Budesonide/formoterol responders 0.60 (0.50–0.71) na 0.69 (0.59–0.80) na
Budesonide/formoterol nonresponders 0.82 (0.72–0.95) na 0.77 (0.66–0.90) na
Formoterol responders 0.71 (0.59–0.86) na 0.85 (0.73–0.99) na
Formoterol nonresponders 1.02 (0.90–1.15) na 0.97 (0.84–1.11) na
Budesonide/formoterol vs formoterol 0.82 (0.71–0.96) 0.012 0.80 (0.69–0.92) 0.002
response (ratio)
responders vs nonresponders 0.71 (0.61–0.83) ,0.001 0.89 (0.77–1.03) 0.11
Budesonide/formoterol responders vs budesonide/formoterol 
nonresponders
0.72 (0.58–0.90) 0.004 0.90 (0.73–1.11) 0.31
Formoterol responders vs formoterol nonresponders 0.70 (0.56–0.87) 0.001 0.88 (0.73–1.07) 0.21
Budesonide/formoterol responders vs formoterol responders 0.84 (0.65–1.08) 0.17 0.81 (0.66–0.99) 0.04
Budesonide/formoterol nonresponders vs formoterol 
nonresponders
0.81 (0.68–0.96) 0.015 0.79 (0.65–0.97) 0.022
Interaction 1.04 (0.77–1.41) 0.81 1.02 (0.76–1.35) 0.92
Notes: aFeV1 response was defined as an improvement in FEV1 of $100 ml. 
bSGRQ response was defined as a reduction (ie, an improvement) in SGRQ total score 
of $4 points.
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Figure 2 exacerbation rates during months 2–12 in patients who received budesonide/formoterol or formoterol alone and who achieved (A) FeV1 response and (B) sgrQ 
improvements above various thresholds at 2 months.
Note: Vertical lines represent the predefined response cut-offs (+100 ml for FeV1 and -4 points for sgrQ total score).














































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




early treatment responses as predictors in COPD
as the minimal CID between measurements.15 A change in 
SGRQ total score of $4 units has been validated as a minimal 
CID in health status measured in mild-to-severe COPD with 
this questionnaire.19 Changes of this magnitude have been 
observed in short- and longer-term trials of bronchodilators in 
COPD.1,7,10 Data from the placebo arms of our analysis show 
that spontaneous increases in FEV
1
 sufficient to exceed the 
100 mL threshold were less frequent than 4-point improve-
ments in the SGRQ total score, reflecting the multiple factors 
that influence health status measurement.
Patients meeting our FEV
1
 response criterion had 
better baseline lung function and took less maintenance 
medication at study entry than nonresponders. These data 
support other studies showing that acute postbronchodila-
tor improvements in FEV
1
 are greater in patients with less 
severe disease.20,21 The chances of a response in SGRQ 
total score from 0 to 2 months were greater than those for 
FEV
1
 response. This was unrelated to baseline lung func-
tion but was more likely if the initial SGRQ total score 
was high, raising the possibility of regression to the mean 
in some cases.
Predicting longer-term response to 
treatment
Over the trial period, 80% of FEV
1
 nonresponders at 2 months 
remained in this group at 12 months, while FEV
1
 responders 
showed more variation, with only 58% of these showing a 
100 mL improvement in FEV
1
 at 2 months still remaining 
responders at 12 months. In contrast, SGRQ responders 
were more likely to sustain their initial improvement and in 
addition, more patients became responders over time. Despite 
these encouraging findings in the whole group, it would be 
difficult to advise an individual patient about his or her future 
lung function or health status based on the change in health 
status at 2 months.
Predicting future exacerbation risk
The investigation of an early response to treatment as a 
predictor of future risk differs from previously published 
studies, which have investigated the predictive utility of 
baseline values. For example, the Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate Endpoints 
(NCT00292552) study22 showed that a wide range of base-
line FEV
1
 and SGRQ values were predictive of exacerbation 
outcomes. Furthermore, a post hoc analysis by Make et al23 
observed that all baseline lung function variables studied 
were strong predictors of severe exacerbations. Conversely, 
other studies have suggested that there is no relationship 
between airflow obstruction characteristics and exacerba-
tion rates.24,25
Based on these contrasting observations, it is clear that 
additional predictors of exacerbation frequency are needed, 
and our data show that early response to treatment offers an 
alternative approach, which has predictive value in some 
(those patients with an early response to FEV
1
, ie, 35.1% of 
patients in our study), but not all patients. A 2-month FEV
1
 
response of $100 mL for both formoterol and budesonide/
formoterol identified patients less likely to exacerbate during 
follow-up. In general, the greater the improvement in FEV
1
, 
the lower the chance of a future exacerbation, although 
we cannot exclude the possibility that other factors may 
contribute to both an FEV
1
 response and a reduction in exac-
erbations. However, FEV
1
 response at 2 months was not the 
only predictive factor, as a between-treatment difference in 
exacerbation risk was still present in nonresponders. This may 
reflect the smaller FEV
1
 responses seen in patients with worse 
initial lung function,26 as changes in operating lung volume 
rather than FEV
1
 are important drivers of exacerbation in such 
patients.27 Our data extend the observations from indacaterol 
trials where change in trough FEV
1
 at 12 weeks was related 
Table 5 Poisson regression analysis of exacerbation rate from 2 to 12 months according to treatment type, baseline FeV1, and sgrQ 
total score, and FeV1 and sgrQ response at 2 months in patients who received budesonide/formoterol or formoterol
Contrast/regression coefficient (95% CI) P-value
FeV1
a
2-month response (per 100 ml) 0.92 (0.89–0.96) ,0.001
Baseline FeV1 (per 100 ml increase) 0.91 (0.90–0.93) ,0.001
Budesonide/formoterol vs formoterolb 0.83 (0.73–0.96) 0.010
sgrQc
2-month response (per 4-point reduction) 0.95 (0.92–0.97) ,0.001
Baseline sgrQ total score (per 4-point reduction) 0.97 (0.95–0.98) ,0.001
Budesonide/formoterol vs formoterolb 0.82 (0.71–0.94) 0.006
Notes: aFeV1 response was defined as an improvement in FEV1 of $100 ml. 
brandomized comparison. cSGRQ response was defined as a reduction (ie, an improvement) 
in sgrQ total score of $4 points.
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to change in exacerbation risk and dyspnea score, although 
a specific, arbitrary threshold value was not utilized.10
Despite the baseline level of health status predicting an 
overall risk of exacerbation in our study, SGRQ response 
at 2 months was not predictive of exacerbation risk over 
2–12 months. Health status is adversely affected by dis-
ease exacerbations,28 and the change in SGRQ total score 
at 2 months may reflect variables other than an effect of 
exacerbation prevention. Although reverse causality cannot 
be excluded, it seems more likely that an SGRQ total score 
responds to previous exacerbation events rather than pre-
dicting the risk of future events. Thus, while a significant 
association is shown for FEV
1
, no such link is evident for 
SGRQ over the score range in the current analysis.
areas for further study
There may be other markers of an early treatment effect 
than those analyzed here. One example could be lung hyper-
inflation, which is not reflected in routine spirometry and 
may be used to measure therapeutic response; however, our 
analysis provides evidence based on responses that are more 
easily measured in primary care. Blood eosinophil count 
may also be a parameter for response to ICS in patients with 
COPD,29 but such data were not available for analysis.
Whether a change that exceeds our threshold values 
occurs at earlier time points and is a comparable or better 
predictor of clinical outcome also needs to be determined. 
Defining responses by early FEV
1
 response has some utility 
when the therapy has the potential to alter that variable, 
although this is not true for all interventions.26
Other considerations
This study has some limitations. Our analysis restricted the 
placebo comparisons to the early 2-month response analysis 
as missing data due to early dropouts significantly reduced 
data quality in the placebo arms of the relevant studies, as 
noted previously.1 The issue of missing data is a frequent 
problem in trials of COPD therapy. The absence of data in 
15% of patients over a 12-month period is not unusual for 
analyses of this type. Loss of data due to discontinuation in 
clinical trials of this type is more frequent on the less effective 
treatment,30 which in the present analysis is formoterol.
Our data were derived from a clinical trial population, 
yet we believe that they have wider clinical relevance as the 
necessity of adding an ICS to a long-acting bronchodilator in 
patients with COPD, and assessing its benefit, is an important 
therapeutic consideration in both primary and secondary care. 
These data also show that a greater proportion of patients 
with COPD receiving budesonide/formoterol demonstrate a 





 and SGRQ are commonly used in specialist clinics to 
assess patient progress. Our results, which were obtained in 
patients with moderate-to-very-severe COPD who had an 
exacerbation in the previous year, suggest that an early response 
at 2 months in either domain is associated with better long-term 
outcomes in that domain and, in the case of improvement in 
FEV
1
, a lower chance of future exacerbations. However, such 
changes occur in a minority of cases and therapeutic benefit 
can also occur in patients who do not have an “early” response 
to treatment. Further investigations and prospective studies are 
needed to identify more sensitive and specific markers of a 
favorable treatment response. The need to assess patients soon 
after treatment is changed is worth considering.
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